Advanced Therapies Integrates 2023
DEVELOPMENT, MANUFACTURE
& IMPLEMENTATION
Exploring the challenges in the journey to widespread adoption of ATMPs, from efficient manufacturing to streamlined NHS implementation.
FUNDING
& SKILLS
Looking at funding opportunities and strategies to overcome the sector-wide skills gap.
Registration and Networking
08:10 – 09:10
Registration and Networking
Welcome & Opening Remarks
09:10 – 09:20
Welcome & Opening Remarks
Sally Ann Forsyth OBE | Chief Executive Officer | Stevenage Bioscience Catalyst
Fireside Chat 1
09:20 – 09:50
Fireside Chat 1: Getting C> to the people who need them
With rapid innovations in the cell and gene therapy arena, how do we integrate breakthrough treatments into routine practice to ensure seamless access for the people living with potentially treatable conditions? How will improved access benefit both people receiving treatments and the wider community?
Speakers Include:
Samantha Barber | Chief Executive | Gene People
Neil Watson | Co-Director | Northern Alliance Advanced Therapies Treatment Centre
Interviewed By:
Nicola Redfern | Consultant | NJ Redfern Ltd
Fireside Chat 2
09:50 – 10:10
Fireside Chat 2: The Future of the ATMP CDMO Market: Challenges and Opportunities
In this interview, we explore the current and future trends of the advanced therapy medicinal products (ATMP) CDMO (Contract Development and Manufacturing) market. We discuss the impact of COVID-19, the basis of competition, the drivers of cost reduction, and the best practices for developing ATMPs at scale.
Speakers Include:
Robert Panting | General Manager ATMP | Rentschler Biopharma
Interviewed By:
Matthew Durdy | Chief Executive Officer | Cell and Gene Therapy Catapult
Session 1
10:15 – 11.05
The right place at the right time
Manufacturing ATMPs requires advanced skills and expensive equipment. Does the UK system of science parks and innovation hubs support access to facilities and expertise?
We used to have more fun
The current economic environment is tough, especially when it comes to funding. When can we expect to see a return to previous levels of funding for the ATMP sector?
Coffee Break
11:05 – 11.30
Networking coffee break
Session 2
11:30 – 12:20
Can we make them cheaper?
Advanced Therapies offer huge benefits, but often at a huge price tag. How can we improve standardisation and reduce the costs of manufacturing?
No Session in this Track
Please choose an alternative track
Session 3
12:25 – 13:15
You’re the Cell to my Gene
The right partner can help you ensure ATMP quality & safety and overcome financial & regulatory hurdles. How do you find the right cell & gene outsourcing partner, and how do you ensure this partnership is productive to both parties?
Tour option: Cytiva – NOW SOLD OUT
Discover the latest instruments to help you overcome your cell and gene therapy process development and manufacturing challenges…
Lunch Break
13.15 – 14.15
Networking lunch break
Session 4
14.15 – 15.05
Not so rare after all
The first success of ATMPs has been seen in rare and complex diseases, but they have potential to go much further. How far and how fast can Advanced Therapies transition into more mainstream indications?
Tour option: Catapult Cell & Gene Therapy
The Cell and Gene Therapy Catapult are providing exclusive tours of their Skills and Training Labs and new Process Analytical Technologies Lab (launched March 2023), to Advanced Therapies Integrates attendees.
Session 5
15.10 – 16.00
I got skills, they’re multiplying
Between 2021 and 2026, the UK advanced therapy and bioprocessing workforce is predicted to increase by over 100%. How can the industry and government work together to attract and retain the skills to support this growth?
An ATMP plan of action
With a 75 year old health service built around more ‘traditional’ methods of treatment, how can we ensure healthcare providers are supported and enabled to rapidly and effectively deploy Advanced Therapies?
Drinks Reception
16.00 – 17.00
Networking drinks reception
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.
Advanced Therapies Integrates 2023
Registration and Networking
08:10 – 09:10
Welcome & Opening Remarks
09.10 – 09.20
Sally Ann Forsyth OBE | Chief Executive Officer | Stevenage Bioscience Catalyst
09.20 – 09.50
Fireside Chat 1: Getting C> to the people who need them
With rapid innovations in the cell and gene therapy arena, how do we integrate breakthrough treatments into routine practice to ensure seamless access for the people living with potentially treatable conditions? How will improved access benefit both people receiving treatments and the wider community?
Speakers Include:
Samantha Barber | Chief Executive | Gene People
Neil Watson | Co-Director | Northern Alliance Advanced Therapies Treatment Centre
Interviewed By:
Nicola Redfern | Consultant | NJ Redfern Ltd
09.50 – 10.10
Fireside Chat 2: The Future of the ATMP CDMO Market: Challenges and Opportunities
In this interview, we explore the current and future trends of the advanced therapy medicinal products (ATMP) CDMO (Contract Development and Manufacturing) market. We discuss the impact of COVID-19, the basis of competition, the drivers of cost reduction, and the best practices for developing ATMPs at scale.
Speakers Include:
Robert Panting | General Manager ATMP | Rentschler Biopharma
Interviewed By:
Matthew Durdy | Chief Executive Officer | Cell and Gene Therapy Catapult
TECHNICAL & PRODUCT
Session 1
10:15 – 11:05
The right place at the right time
Manufacturing ATMPs requires advanced skills and expensive equipment. Does the UK system of science parks and innovation hubs support access to facilities and expertise?
Coffee break & Networking
11:05 – 11:30
Session 2
11:30 – 12:20
Can we make them cheaper?
Advanced Therapies offer huge benefits, but often at a huge price tag. How can we improve standardisation and reduce the costs of manufacturing?
Session 3
12:25 – 13:15
You’re the Cell to my Gene
The right partner can help you ensure ATMP quality & safety and overcome financial & regulatory hurdles. How do you find the right cell & gene outsourcing partner, and how do you ensure this partnership is productive to both parties?
Lunch break & Networking
13:15 – 14:15
Session 4
14:15 – 15:05
Not so rare after all
The first success of ATMPs has been seen in rare and complex diseases, but they have potential to go much further. How far and how fast can Advanced Therapies transition into more mainstream indications?
Session 5
15:10 – 16:00
I got skills, they’re multiplying
Between 2021 and 2026, the UK advanced therapy and bioprocessing workforce is predicted to increase by over 100%. How can the industry and government work together to attract and retain the skills to support this growth?
Networking drinks reception
16:00 – 17:00
COMMERCIAL, FINANCE
& MONEY
Session 1
10:15 – 11:05
We used to have more fun
The current economic environment is tough, especially when it comes to funding. When can we expect to see a return to previous levels of funding for the ATMP sector?
Coffee break & Networking
11:05 – 11:30
Session 2
11:30 – 12:20
Tour option: Cytiva
12:25 – 13:15
Tour option: Cytiva – NOW SOLD OUT
Discover the latest instruments to help you overcome your cell and gene therapy process development and manufacturing challenges.
Be empowered to lead preclinical- to commercial-stage cell therapy development. Experience scalable processes — and the acceleration of optimized therapy delivery — with our digitally integrated platform across cell processing, cell expansion, and cryopreservation.
From upstream cell culture to downstream purification, our viral vector process uses modern tools and technologies and is easy scaled. Check out the ÄKTA™ avant and Biacore™ systems for purification and analytics, and our newest addition, cell line development.
Don’t miss this opportunity to get hands on experience with some of Cytiva’s instruments in the lab and chat with our subject matter experts about your specific challenges.
The lab is only a short walk away from the Advanced Therapies Integrates conference, within Stevenage Bioscience Catalyst itself.
Lunch break & Networking
13:15 – 14:15
Tour option: Catapult Cell & Gene Therapy
14:15 – 15:05
Tour option: Catapult Cell & Gene Therapy
The Cell and Gene Therapy Catapult are providing exclusive tours of their Skills and Training Labs and new Process Analytical Technologies Lab (launched March 2023), to Advanced Therapies Integrates attendees.
CGT Catapult staff will provide in-depth tours of these facilities, where you will have the opportunity to learn about the technology and processes that take place in these labs and ask any questions that you may have to the experts that run these sites.
Learn more:Â https://ct.catapult.org.uk/facilities/stevenage
Register now for tours of the Cell and Gene Therapy Catapult Lab by emailing Kevin Gwilliam – comms@ct.catapult.org.uk.
Session 5
15:10 – 16:00
An ATMP plan of action
With a 75 year old health service built around more ‘traditional’ methods of treatment, how can we ensure healthcare providers are supported and enabled to rapidly and effectively deploy Advanced Therapies?
Networking drinks reception
16:00 – 17:00
Sign up for life science integrates news
Get the latest news and updates by signing up today.
By signing up to the life science integrates newsletter, you have read and agree to our Privacy Policy, including our Cookie use.